Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma (2024)

Abstract

Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.

Original languageEnglish
Article numberhyp183
Pages (from-to)425-431
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number5
DOIs
StatePublished - Jan 19 2010

ASJC Scopus Subject Areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Keywords

  • Chemo-Phase II
  • Head and neck
  • Radiation oncology

Access to Document

OpenUrl availability

Full text

Other files and links

Cite this

  • APA
  • Standard
  • Harvard
  • Vancouver
  • Author
  • BIBTEX
  • RIS

Zheng, J., Wang, G., Yang, G. Y., Wang, D., Luo, X., Chen, C., Zhang, Z., Li, Q., Xu, W., Li, Z., & Wang, D. (2010). Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Japanese Journal of Clinical Oncology, 40(5), 425-431. Article hyp183. https://doi.org/10.1093/jjco/hyp183

Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. / Zheng, Jijun; Wang, Ge; Yang, Gary Y. et al.
In: Japanese Journal of Clinical Oncology, Vol. 40, No. 5, hyp183, 19.01.2010, p. 425-431.

Research output: Contribution to journalArticlepeer-review

Zheng, J, Wang, G, Yang, GY, Wang, D, Luo, X, Chen, C, Zhang, Z, Li, Q, Xu, W, Li, Z & Wang, D 2010, 'Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma', Japanese Journal of Clinical Oncology, vol. 40, no. 5, hyp183, pp. 425-431. https://doi.org/10.1093/jjco/hyp183

Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C et al. Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Japanese Journal of Clinical Oncology. 2010 Jan 19;40(5):425-431. hyp183. doi: 10.1093/jjco/hyp183

Zheng, Jijun ; Wang, Ge ; Yang, Gary Y. et al. / Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. 5. pp. 425-431.

@article{e5a0d133f6b74936a3eb3b0633eca368,

title = "Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma",

abstract = "Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.",

keywords = "Chemo-Phase II, Head and neck, Radiation oncology",

author = "Jijun Zheng and Ge Wang and Yang, {Gary Y.} and Daoyuan Wang and Xizhong Luo and Chuan Chen and Zhimin Zhang and Qiong Li and Wen Xu and Zengpeng Li and Dong Wang",

note = "Funding Information: The research was supported in part by grants from the National Science Foundation of China (No. 30370341 and No. 30570410) and the Academic Foundation for Authors of National Excellent Doctoral Dissertation of China (No. 200261).",

year = "2010",

month = jan,

day = "19",

doi = "10.1093/jjco/hyp183",

language = "English",

volume = "40",

pages = "425--431",

journal = "Japanese Journal of Clinical Oncology",

issn = "0368-2811",

number = "5",

}

TY - JOUR

T1 - Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma

AU - Zheng, Jijun

AU - Wang, Ge

AU - Yang, Gary Y.

AU - Wang, Daoyuan

AU - Luo, Xizhong

AU - Chen, Chuan

AU - Zhang, Zhimin

AU - Li, Qiong

AU - Xu, Wen

AU - Li, Zengpeng

AU - Wang, Dong

N1 - Funding Information:The research was supported in part by grants from the National Science Foundation of China (No. 30370341 and No. 30570410) and the Academic Foundation for Authors of National Excellent Doctoral Dissertation of China (No. 200261).

PY - 2010/1/19

Y1 - 2010/1/19

N2 - Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.

AB - Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.

KW - Chemo-Phase II

KW - Head and neck

KW - Radiation oncology

UR - http://www.scopus.com/inward/record.url?scp=77952559137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952559137&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyp183

DO - 10.1093/jjco/hyp183

M3 - Article

C2 - 20085903

SN - 0368-2811

VL - 40

SP - 425

EP - 431

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

IS - 5

M1 - hyp183

ER -

Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Aron Pacocha

Last Updated:

Views: 5388

Rating: 4.8 / 5 (48 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Aron Pacocha

Birthday: 1999-08-12

Address: 3808 Moen Corner, Gorczanyport, FL 67364-2074

Phone: +393457723392

Job: Retail Consultant

Hobby: Jewelry making, Cooking, Gaming, Reading, Juggling, Cabaret, Origami

Introduction: My name is Aron Pacocha, I am a happy, tasty, innocent, proud, talented, courageous, magnificent person who loves writing and wants to share my knowledge and understanding with you.